Verrica Pharmaceuticals (VRCA)

Executive Summary

Verrica Pharmaceuticals is a commercial-stage dermatology company with a proven track record, having secured FDA approval for YCANTH (VP-102) for the treatment of molluscum contagiosum, a common viral skin infection in children. YCANTH is the first-ever therapy approved for this indication, addressing a significant unmet need. The company is now focused on expanding its pipeline, which includes VP-315 for basal cell carcinoma (BCC) and VP-102 for common warts. A completed Phase 2 trial of VP-315 in BCC has shown promising results, and Verrica is preparing to advance this program into pivotal trials. Meanwhile, the company continues to commercialize YCANTH, with growing prescription trends and expanding payer coverage. With a strong balance sheet and a clear strategic focus on in-office dermatological treatments, Verrica is positioned to build a durable franchise in viral skin diseases and non-melanoma skin cancers. The near-term outlook is centered on commercial execution and pipeline progression, with several upcoming catalysts that could drive significant value.

Upcoming Catalysts (preview)

• Q3 2026End-of-Phase 2 meeting with FDA for VP-315 in basal cell carcinoma80% success
• Q3 2026Q2 2026 earnings report highlighting YCANTH revenue growth and commercial traction90% success
• H1 2027Initiation of Phase 3 trial for VP-102 in common warts60% success